Author

P. Ruemmele

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Grujovic· 1 shared A. M. Schlitter· 1 shared B. Polzer· 1 shared C. A. Klein· 1 shared C. Botteron· 1 shared C. Irlbeck· 1 shared C. Koestler· 1 shared C. Pilarsky· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Grujovic

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma

M. P. de Andres, R. Jackson, C. Pilarsky, A. M. Schlitter, E. Costello, W. Greenhalf, P. Ganeh, T. Knoesel, D. Palmer, P. Ruemmele, W. Weichert, M. Buechler, T. Hackert, J. P. Neoptolemos, N. Malats, , F. X. Real

This study shows that low GATA4 and GATA6 expression in pancreatic ductal adenocarcinoma (PDAC) is linked to worse patient outcomes and loss of the classical tumor phenotype.

bioRxiv · Aug 9, 2021Cancer Biology

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency

M. Werner-Klein, A. Grujovic, C. Irlbeck, M. Obradovic, M. Hoffmann, H. Koerkel-Qu, X. Lu, S. Treitschke, C. Koestler, C. Botteron, K. Weidele, C. Werno, B. Polzer, S. Kirsch, M. Guzvic, , C. A. Klein

The paper identifies IL6 trans-signaling as a mechanism supporting DCC survival and outgrowth during clinical latency, with microenvironmental dependencies and PIK3CA mutations linked to metastatic progression.

bioRxiv · May 28, 2020Cancer Biology